Exicure, Inc. (NASDAQ:XCUR) Major Shareholder Acquires $711,669.00 in Stock

Exicure, Inc. (NASDAQ:XCUR) major shareholder Co. Ltd. Dgp acquired 237,223 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were purchased at an average price of $3.00 per share, with a total value of $711,669.00. Following the completion of the transaction, the insider now owns 849,223 shares of the company’s stock, valued at $2,547,669. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Exicure Price Performance

Shares of XCUR traded up $0.66 during trading hours on Monday, hitting $2.26. 18,970,292 shares of the stock were exchanged, compared to its average volume of 377,786. Exicure, Inc. has a fifty-two week low of $1.44 and a fifty-two week high of $4.75. The business has a 50-day moving average of $0.53 and a 200-day moving average of $0.25. The firm has a market capitalization of $19.55 million, a P/E ratio of -1.49 and a beta of 1.24.

Exicure (NASDAQ:XCUR) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.01) earnings per share for the quarter.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.